DNA methylation profiles and their relationship with cytogenetic status in adult acute myeloid leukemia

Autor: Javier Suela, Juan C. Cigudosa, Alba Maiques, Agustín F. Fernández, Xabier Agirre, Manel Esteller, Sara Alvarez, Sandra Rodriguez Perales, Mark Wunderlich, Francesco Acquadro, Ana Valencia, José I. Martín-Subero, Felipe Prosper, Miguel A. Sanz, María José Calasanz, José Cervera, Reiner Siebert, Jose Roman-Gomez, James C. Mulloy
Přispěvatelé: Universitat de Barcelona
Jazyk: angličtina
Rok vydání: 2010
Předmět:
Male
Myeloid
Oncogene Proteins
Fusion

lcsh:Medicine
Epigenesis
Genetic

Fusion gene
Epigènesi
hemic and lymphatic diseases
Chromosomes
Human

lcsh:Science
Genetics
Multidisciplinary
Hematology/Acute Myeloid Leukemia
Myeloid leukemia
Methylation
Middle Aged
Prognosis
Leukemia
Myeloid
Acute

Leukemia
medicine.anatomical_structure
DNA methylation
Female
Karyotypes
Metilació
Research Article
Ciencias de la Salud::Oncología [Materias Investigacion]
Adult
Leucèmia mieloide
Citogenètica
Biology
Cytogenetics
Genetics and Genomics/Epigenetics
medicine
Humans
Epigenetics
Genetics and Genomics/Genomics
Genetics and Genomics/Cancer Genetics
Cariotips
Tumor Suppressor Proteins
lcsh:R
Genetic Variation
Adult Acute Myeloid Leukemia
DNA Methylation
medicine.disease
Genetics and Genomics/Disease Models
Karyotyping
Cancer research
lcsh:Q
Epigenesis
Zdroj: Recercat. Dipósit de la Recerca de Catalunya
instname
Dipòsit Digital de la UB
Universidad de Barcelona
Dadun. Depósito Académico Digital de la Universidad de Navarra
PLoS ONE
PLoS ONE, Vol 5, Iss 8, p e12197 (2010)
Popis: Background: Aberrant promoter DNA methylation has been shown to play a role in acute myeloid leukemia (AML) pathophysiology. However, further studies to discuss the prognostic value and the relationship of the epigenetic signatures with defined genomic rearrangements in acute myeloid leukemia are required. Methodology/Principal Findings: We carried out high-throughput methylation profiling on 116 de novo AML cases and we validated the significant biomarkers in an independent cohort of 244 AML cases. Methylation signatures were associated with the presence of a specific cytogenetic status. In normal karyotype cases, aberrant methylation of the promoter of DBC1 was validated as a predictor of the disease-free and overall survival. Furthermore, DBC1 expression was significantly silenced in the aberrantly methylated samples. Patients with chromosome rearrangements showed distinct methylation signatures. To establish the role of fusion proteins in the epigenetic profiles, 20 additional samples of human hematopoietic stem/ progenitor cells (HSPC) transduced with common fusion genes were studied and compared with patient samples carrying the same rearrangements. The presence of MLL rearrangements in HSPC induced the methylation profile observed in the MLL-positive primary samples. In contrast, fusion genes such as AML1/ETO or CBFB/MYH11 failed to reproduce the epigenetic signature observed in the patients. Conclusions/Significance: Our study provides a comprehensive epigenetic profiling of AML, identifies new clinical markers for cases with a normal karyotype, and reveals relevant biological information related to the role of fusion proteins on the methylation signature
Databáze: OpenAIRE